5-chloro-N-phenylpyrazine-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-N-phenylpyrazine-2-carboxamide
• 英文别名: 5-Chloro-N-phenylpyrazine-2-carboxamide
• 化学式: C₁₁H₈ClN₃O
• 分子量: 233.657
• InChiKey: OUQKDXJFAHJQRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-chloro-N-phenylpyrazine-2-carboxamide 在 ammonium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 0.75h， 以79%的产率得到5-amino-N-phenylpyrazine-2-carboxamide
  参考文献：
  名称：

  Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides

  摘要：

  Substitution of chlorine in 5-chloro-N-phenylpyrazine-2-carboxamide (1) with simple n-alkylamines yielded a series of 5-alkylamino-N-phenylpyrazine-2-carboxamides (propylamino to octylamino derivatives), which possessed similar or increased activity against Mycobacterium tuberculosis H37Rv compared to parent 5-chloro derivative (1), with MIC ranging from 2.5 to 12.2 μM. 5-Butylamino to 5-heptylamino derivatives exerted similar activity also against Mycobacterium kansasii. Importantly, the substitution led also to significant decrease of in vitro cytotoxicity in HepG2 cell line. 5-Heptylamino-N-phenylpyrazine-2-carboxamide (1e) exerted MIC=2.5 μM (M.tbc) and IC50 >250 μM (HepG2). Further modification of alkylamino chain with terminal methoxy or hydroxy group lead to compounds with decreased or none activity, the decrease was proportional to the decrease of lipophilicity. 5-(2-Phenylethylamino) and 5-(3-phenylpropylamino) derivatives were also of decreased activity. On contrary to alkylamino derivatives derived from 1, alkylamino derivatives derived from 5-chloro-N-2-chlorophenylpyrazine-2-carboxamide (2) possessed substantially decreased or none activity. None of the prepared compounds was active against Mycobacterium avium.

  DOI：

  10.1016/j.bmc.2014.11.014
• 作为产物：
  描述：

  5-羟基吡嗪-2-羧酸 在 氯化亚砜 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 1.5h， 生成 5-chloro-N-phenylpyrazine-2-carboxamide
  参考文献：
  名称：

  5-Chloro-N-phenylpyrazine-2-carboxamides 的合成、抗分枝杆菌活性和体外细胞毒性

  摘要：

  5-氯吡嗪酰胺 (5-Cl-PZA) 是分枝杆菌脂肪酸合酶 I 的抑制剂，在体外具有广谱抗分枝杆菌活性。一些在吡嗪和苯基核上具有不同取代基的 N-苯基吡嗪-2-甲酰胺对结核分枝杆菌具有显着的体外活性。为了测试结合 5-Cl-PZA 和苯胺基序的结构的活性，合成了一系列三十个 5-氯-N-苯基吡嗪-2-甲酰胺，在苯环上具有各种取代基 R，并针对结核分枝杆菌 H37Rv 进行筛选， M. kansasii 和两个 M. avium 菌株。大多数化合物对结核分枝杆菌 H37Rv 的活性范围为 MIC = 1.56–6.25 µg/mL，只有三种衍生物无活性。分子的苯基部分耐受许多不同的取代基，同时保持活性。具有羟基取代基的化合物的体外细胞毒性降低，优选与其他亲水性取代基组合。5-氯-N-(5-氯-2-羟基苯基)吡嗪-2-甲酰胺 (21) 抑制所有测试菌株（MIC = 1.56 µg/mL 结核分枝杆菌；12

  DOI：

  10.3390/molecules181214807

文献信息

• SUBSTITUTED BENZAMIDE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3187490A1

  公开（公告）日：2017-07-05

  The invention relates to compounds of formula wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2Cl)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O-CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R" is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式化合物 式中 R 是氢或低级烷基； R1 是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基任选被低级烷基、羟基、卤素或-(CH2)p-芳基取代； n 为 0、1 或 2； o 为 0 或 1； p 为 0、1 或 2； R2 是 CF3、环烷基，可选择被低级烷氧基或卤素取代，或者是茚-2-基，或者是杂环烷基，可选择被杂芳基取代、 或芳基或杂芳基，其中芳环可选择被一个或两个取代基取代，这些取代基可选 自低级烷基、卤素、杂芳基、羟基、CF3、OCF3、OCH2CF3、OCH2-环烷基、OCH2C(CH2OH)(CH2Cl)(CH3)低级烷氧基、CH2-低级烷氧基、低级烷基或氰基，或被-C(O)-苯基、-O-苯基、-O-CH2-苯基、苯基或-CH2-苯基取代，其中苯基环可任选被卤素、-C(O)-低级烷基、-C(O)OH 或-C(O)O-低级烷基取代、 或芳香环可任选被杂环烷基、OCH2-氧杂环丁烷-3-基或 O-四氢吡喃-4-基（可任选被低级烷基取代）取代； X 是键； Y 是键或 -CH2- R' 是氢或低级烷基、 R" 是氢、低级烷基、CF3、低级烷氧基、 q 是 0、1、2 或 3； 或其药理上合适的酸加成盐。 现已发现，式 I 的化合物对痕量胺相关受体（TAARs），尤其是 TAAR1 具有良好的亲和力。 这些化合物可用于治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍（ADHD）、应激相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、药物滥用和其他疾病、偏头痛、高血压、药物滥用和代谢紊乱，如饮食紊乱、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和同化紊乱、体温平衡紊乱和失调、睡眠和昼夜节律紊乱以及心血管疾病。
• Synthesis, Antimycobacterial Activity and In Vitro Cytotoxicity of 5-Chloro-N-phenylpyrazine-2-carboxamides
  作者：Jan Zitko、Barbora Servusová、Pavla Paterová、Jana Mandíková、Vladimír Kubíček、Radim Kučera、Veronika Hrabcová、Jiří Kuneš、Ondřej Soukup、Martin Doležal

  DOI：10.3390/molecules181214807

  日期：——

  tuberculosis H37Rv, M. kansasii and two strains of M. avium. Most of the compounds exerted activity against M. tuberculosis H37Rv in the range of MIC = 1.56–6.25 µg/mL and only three derivatives were inactive. The phenyl part of the molecule tolerated many different substituents while maintaining the activity. In vitro cytotoxicity was decreased in compounds with hydroxyl substituents, preferably combined

  5-氯吡嗪酰胺 (5-Cl-PZA) 是分枝杆菌脂肪酸合酶 I 的抑制剂，在体外具有广谱抗分枝杆菌活性。一些在吡嗪和苯基核上具有不同取代基的 N-苯基吡嗪-2-甲酰胺对结核分枝杆菌具有显着的体外活性。为了测试结合 5-Cl-PZA 和苯胺基序的结构的活性，合成了一系列三十个 5-氯-N-苯基吡嗪-2-甲酰胺，在苯环上具有各种取代基 R，并针对结核分枝杆菌 H37Rv 进行筛选， M. kansasii 和两个 M. avium 菌株。大多数化合物对结核分枝杆菌 H37Rv 的活性范围为 MIC = 1.56–6.25 µg/mL，只有三种衍生物无活性。分子的苯基部分耐受许多不同的取代基，同时保持活性。具有羟基取代基的化合物的体外细胞毒性降低，优选与其他亲水性取代基组合。5-氯-N-(5-氯-2-羟基苯基)吡嗪-2-甲酰胺 (21) 抑制所有测试菌株（MIC = 1.56 µg/mL 结核分枝杆菌；12
• Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides
  作者：Jan Zitko、Barbora Servusová、Alena Janoutová、Pavla Paterová、Jana Mandíková、Vladimír Garaj、Marcela Vejsová、Jan Marek、Martin Doležal

  DOI：10.1016/j.bmc.2014.11.014

  日期：2015.1

  Substitution of chlorine in 5-chloro-N-phenylpyrazine-2-carboxamide (1) with simple n-alkylamines yielded a series of 5-alkylamino-N-phenylpyrazine-2-carboxamides (propylamino to octylamino derivatives), which possessed similar or increased activity against Mycobacterium tuberculosis H37Rv compared to parent 5-chloro derivative (1), with MIC ranging from 2.5 to 12.2 μM. 5-Butylamino to 5-heptylamino derivatives exerted similar activity also against Mycobacterium kansasii. Importantly, the substitution led also to significant decrease of in vitro cytotoxicity in HepG2 cell line. 5-Heptylamino-N-phenylpyrazine-2-carboxamide (1e) exerted MIC=2.5 μM (M.tbc) and IC50 >250 μM (HepG2). Further modification of alkylamino chain with terminal methoxy or hydroxy group lead to compounds with decreased or none activity, the decrease was proportional to the decrease of lipophilicity. 5-(2-Phenylethylamino) and 5-(3-phenylpropylamino) derivatives were also of decreased activity. On contrary to alkylamino derivatives derived from 1, alkylamino derivatives derived from 5-chloro-N-2-chlorophenylpyrazine-2-carboxamide (2) possessed substantially decreased or none activity. None of the prepared compounds was active against Mycobacterium avium.